MANATT, PHELPS, AND PHILLIPS

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 6, 2026

Income

$70,000.00

What the client paid this registrant for the period.

Client based in

California

Lobbying activity 1

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Rare disease drug development

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.